Red blood cell depletion and one with 20% DMSO alone, the other with 10% DMSO ϩ 12% HES. Equal volumes of cell suspension and cryopro-
cryopreservation of umbilical cord blood tectant solution were mixed before cryopreservation in ster-
(UCB)
ile cryogenic vials in order to achieve a final concentration of 10% DMSO and 5% DMSO ϩ 6% HES (Stiff et al 6 and Makino et al 7 ). After thawing, no clumping was seen Recently, Donaldson et al 1 reported the effects of various and recovery of NC, CD34 ϩ cells and cell viability was cryoprotectant concentrations of DMSO and HES very high and comparable to that seen with the cryoprotec-(hydroxyethyl starch) and different cooling rates ranging tive solution containing 10% DMSO alone. In our series, from 1 to 10°C/min to determine the best recovery and tolthe final concentration of NC was slightly higher (1.4 ϫ erance of progenitor cells after thawing. Their results were 10 7 /ml s.d. Ϯ 0.8) but no problem of cell clumping was as follows: (1) high recovery of colony-forming cells observed. The use of DNase can be effective in preventing (CFC) and CD34 ϩ cells were obtained with two rounds lysis of clumps but the risk of allergic or febrile reactions of 3% gelatin sedimentation; (2) varying concentrations of for a product not manufactured to pharmaceutical standards HES had no effect on cell survival, did not reduce the probis a major concern, thus use of HES is recommended lem of cell clumping and the use of DNase was sometimes because it does not need to be removed before infusion. 8 required; (3) no significant differences between 5 and 10% Recently, Galmes et al 9 demonstrated the possibility of DMSO cryoprotective solutions were noted in terms of cell cryopreserving and storing peripheral blood stem cells viability and CD34
ϩ cell recovery, but a concentration of using 5% DMSO as the sole cryoprotectant. Donaldson et 7.5% DMSO would be recommended for routine proal 1 reported that this low concentration of DMSO can be cessing of UCB; (4) cooling rate of 1°C/min allowed a used in UCB cryopreservation and has no deleterious effect good recovery in CD34 ϩ cells as compared with 5-on progenitor cell recovery. This is an important issue, 10°C/min. because DMSO can be toxic if large amounts are infused Our group recently investigated a procedure for red into small patients. 8 blood cell (RBC) depletion 2,3 and different cryoprotective Cooling rate and the concentration of the cryoprotectant solutions with or without rate-controlled freezing 4 in an represent two of the main factors upon which the survival attempt to develop an inexpensive and simple method for of frozen cells depends, and thus Donaldson et al 1 recprocessing and cryopreserving UCB haemopoietic cells.
ommended a controlled cooling rate of 1°C/min and 7.5% Our experience of 40 UCB samples showed that RBC of DMSO. Another critical factor is the optimal post-freezdepletion by double gravity sedimentation with HES ing plateau which must be less than 4 min for the maximum (Plasmasteril, hydroxyethyl starch 6% in 0.9 NaCl; Fresenprogenitor cell recovery. 8 In this context, we observed that ius, Germany) yields similar results to those obtained with a Ϫ80°C mechanical cryopreservation provides a cooling 3% gelatin (92.9, 90.5 and 83.8% recoveries for nucleated rate of approximately 3°C/min and the post-freezing placells, CD34
ϩ cells and CFU-GM, respectively). In compariteau lasts for less than 4 min. 7-9 Our data on red cellson with gelatin, HES does not require any laboratory prepdepleted UCB samples cryopreserved using 5% DMSO ϩ aration since it is commercially available, and in agreement 6% HES in a Ϫ80°C freezer and then transferred into a with Bertolini et al 5 it can be used in a closed system, thus liquid nitrogen tank showed a high recovery of progenitor avoiding possible microbial contamination during handling. cells (Table 1) . Concerning the role of HES, it is probable that at a low Further studies regarding the recovery of haematopoietic concentration (4% or less) this extra-cellular cryoprotectant progenitor cells after a longer period of storage are necesis not effective and cannot reduce post-thawing lysis and cell clumping. We studied two cryoprotective solutions:
sary, but the possibility of cryopreserving RBC-depleted First, we used collection into large syringes with heparin normal birth represent a potential personal biological spare followed by centrifugation (900 g for 5 min) in an open part. The material's medical usefulness has been amply hood, retrieval of buffy coat and transfer into four vials demonstrated after the pioneering transplantation of Gluckwith 1 ml of freezing medium in each (RPMI 1640 with man and collaborators.
1 Furthermore, syngeneic and allo-30% fetal calf serum and 15% DMSO on ice). We realized geneic transplantation of hematopoietic stem cells is too late that freezing in the patient's own plasma would increasingly being used.
have been better. Sampling by gravity drainage into closed Fetal stem cells can be obtained from placentas without freezing bags with 10 ml of acid-citrate-dextrose (ACD) involving the child by means of a simple procedure. This and 2 IU heparin/ml was carried out in the last months of yields material which is usually uninfected and without the the test period. In addition, 6 ϫ 1 ml of blood were taken mutations acquired later in life. In several places pregnant into separate vials to have cell specimens available to verify women are therefore offered the opportunity to have cord HLA identity. After weighing, an equal volume of freezing blood stored as a precaution against a donor illness later in medium was slowly added on ice, and the unseparated life that might require stem cell replacement. So far, storing blood was stored. In all cases freezing was done in an elecof cord blood in the USA has to a large extent been limited tric, Ϫ140°C freezer followed by transfer to nitrogen vapby the high cost which must necessarily be charged to our. the parents.
During the project's 2-year period, 1517 women were We have carried out a pilot study of free-of-charge coleligible, of which 89% chose to participate. Our ethical lection of cord blood in one provincial maternity clinic in permission did not allow questioning about reasons for Denmark. The study should give answers to the following deciding not to join the project. questions: (1) acceptability, (2) technical feasibility and When the staff was asked to collect as much as possible, (3) cost.
a mean of 60 ml Ϯ 25 was collected by suction into Our study population consisted of healthy women giving syringe, whereas the method with gravity collecting into birth at the public regional maternity clinic at Fredericia closed bags gave an average of 80 ml Ϯ 15. Viability of Hospital, Denmark, which serves an area of approximately nucleated cells (including granulocytes) as tested by typan 90 000 people. When going for the first predelivery checkblue exclusion upon rethawing 24 samplings of buffy coat up at week 14, the women (in accordance with the rules laid down by the Ethical Committee) were orally and in and 12 samplings of total blood in bags varied between 45% and 95%. The mean was 65% for both types of handable to the Danish population, an ordinary public maternity clinic can handle the collection, and the cost is far less than ling. The cost for the 2-year collection activity was calculated by the hospital administration. Gustav Wieds Vej 10, DK-8000 ling plastic bags) set at 1/8 per year gave a cost of ECU E Ebbesen Aarhus C, Denmark 5000, renting of space and surveillance ECU 4000. The cost K Füchsel of keeping a person's samples, nitrogen and depreciation on P Petersen nitrogen container will therefore be ECU 10 per year for JH Ebbesen each child when collection is done into small vials, and J Abildtrup ECU 20 when whole blood is kept in plastic bags. This P Schiøler adds up to a lifetime expense in the range of ECU 800 to 1550. Ongoing international work on defining good laboratory practice will require more costly procedures than used here, both for sampling and quality control, stem cell counts, viability and sterility. However, initially autologous collection only requires quality collection, while testing can be left to those cases where the blood is needed later in Acknowledgements life. Furthermore, if collecting becomes part of normal birth practice, the larger market and rationalization will reduce 
experience
Here we report 61 patients mobilised with cyclophosphamide (CY) 3 g/m 2 and G-CSF 5 g/kg/day between March 1995 and December 1996. Median age was 45 years High-dose chemotherapy followed by infusion of autolog-(range 18-68) and underlying diagnoses were NHL (30), ous peripheral blood stem cells (PBSC) is now a well estabmyeloma (14), Hodgkin's disease (10), solid tumours (five) lished treatment of haematological and non-haematological and ALL (two). They received a single dose of CY (day malignancies.
1 However, it is still unclear which method 0) in an outpatient setting as per the protocol shown in of mobilising PBSC is most optimal. The combination of Table 1 . G-CSF (Neupogen, Roche, Switzerland) chemotherapy (CT) and recombinant haematopoietic 5 g/kg/day subcutaneously was started 24 h after CY and growth factors (HGF) 2 is most widely used but controcontinued until the last day of leukapheresis (LP). Measureversies still exist concerning the dosage and kind of ments of complete blood counts and CD34 + cells were commobilising HGF and CT agent -these should be effective menced on day 7 after CY administration and LP were in providing sufficient PBSC mobilisation, safe, ie with low initiated when the WBC reached more than 1.0 × 10 9 /l and haematological and non-haematological toxicity, and lastly a distinct population of CD34 + cells could be detected or providing a possible in vivo purging effect. In view of the (from August 1996) when more then 10 CD34 + cells/l increasing number of transplants there is evergrowing were counted. Harvesting proceeded until a target of in the majority of patients with a minimal degree of complications and with good predictability of harvesting. This is in agreement with the data of Mahendra et al 6 who recently showed similar satisfactory results with the same protocol. (Table 2) , ie yield less Czech Republic than 1 × 10 6 CD34 + cells/kg or an insufficient CD34 + count in the peripheral blood for LP initiation, all of them being heavily pretreated and/or irradiated in the past. All aphereses were performed on days 7-13 after CY administration, References with the majority of patients and with the best CD34 + yields in day 8 (Table 3) . There was no procedure-related death 
